Paper Details

  1. Home
  2. Paper Details

Novel agents for renal cell carcinoma require novel selection paradigms to optimise first-line therapy.

Author: SchmidingerManuela, ZielinskiChristoph C

ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

The availability of first-line therapies for metastatic renal cell carcinoma (RCC) has increased rapidly with the introduction of three novel agents: sunitinib, temsirolimus, and bevacizumab (in combination with interferon [IFN]). This expansion makes selecting the optimal therapy for individual patients more challenging and crucial. Currently, a treatment algorithm based on tumor histology and patient risk status guides clinical practice, but it doesn't always identify specific treatment for individual patients, particularly for those with favorable or intermediate-risk clear cell RCC. Treatment selection for these patients should consider potential for cure and optimal progression-free survival (PFS) with good tolerability and quality of life. Bevacizumab combined with IFN may be the treatment of choice for patients with a realistic opportunity for cure. However, sunitinib and bevacizumab combined with IFN yield similar PFS. Therefore, if optimal PFS is the treatment goal, other factors, such as patient-related factors (needs, circumstances, comorbidities) and the associated side effects of bevacizumab combined with IFN and sunitinib, should be considered. The review discusses these factors in detail, highlighting factors that may lead to the selection of bevacizumab combined with IFN or sunitinib for individual patients.
Paper Details　
Original Abstract of the Article :
First-line therapies available for metastatic renal cell carcinoma (RCC) have increased rapidly with the recent introduction of three novel agents: sunitinib, temsirolimus and bevacizumab (in combination with interferon [IFN]). This expansion means that the selection of the optimal therapy for indiv...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.ctrv.2009.01.004

データ提供：米国国立医学図書館（NLM）

Navigating the Desert of Renal Cell Carcinoma Treatment

The field of metastatic renal cell carcinoma (RCC) treatment is expanding like a vast desert, with new therapies constantly emerging. This study delves into the complexities of selecting the optimal first-line therapy for patients with this challenging disease. The authors investigated the effectiveness of three novel agents: sunitinib, temsirolimus, and bevacizumab (in combination with interferon [IFN]). They used a treatment algorithm based on tumor histology and patient risk status, exploring the factors that influence treatment selection, such as the potential for cure and progression-free survival (PFS). The authors highlight the importance of considering patient-related factors, including their individual needs, circumstances, and comorbidities, along with the potential side effects of each therapy. This research serves as a valuable guide for clinicians navigating the ever-evolving landscape of RCC treatment.

A New Oasis in the Desert?

This study suggests that for patients with a realistic chance of cure, bevacizumab combined with IFN might be the most effective option. However, the authors acknowledge that sunitinib and bevacizumab combined with IFN produce similar PFS, indicating that other factors, such as patient-specific needs and potential side effects, should be carefully considered when selecting the best treatment pathway.

Keeping an Eye on the Horizon

This research highlights the importance of individualized treatment approaches in RCC. It emphasizes the need to carefully evaluate patient-specific factors, such as age, overall health, and lifestyle, when selecting the most appropriate therapy. The desert of RCC treatment can be overwhelming, but with careful consideration and a tailored approach, patients can find their own path to optimal care and hopefully, a cure.

Dr. Camel's Conclusion

This study provides a detailed analysis of the available first-line therapies for metastatic renal cell carcinoma, acknowledging the importance of individualized treatment plans. It's like finding a clear path through a vast desert! By understanding the nuances of each therapy and considering patient-specific factors, clinicians can make informed decisions that provide patients with the best chance of success.

Date :
  1. Date Completed 2009-04-21
  2. Date Revised 2018-12-01
Further Info :

Pubmed ID

19232474

DOI: Digital Object Identifier

10.1016/j.ctrv.2009.01.004

Related Literature

Article Analysis
・Side Effects of temsirolimus
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.